Articles On Biotron (ASX:BIT)

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Biotron has announced preliminary analyses of data from the BIT225-010 Phase 2 clinical trial of its lead antiviral drug BIT225.

05 Apr 2024 - A snapshot of the stocks on the move, featuring Linius Technologies Ltd (ASX:LNU), Biotron Limited (ASX:BIT) and Elixir Energy (ASX:EXR).

Biotron (ASX: BIT) has obtained promising early results from a phase 2 clinical trial of the company’s lead antiviral drug BIT225. Preliminary analysis of trial data indicates BIT225 is having a unique effect beyond that seen with the curre...

  To register for today's webinar click here. Linius Technologies Ltd (ASX:LNU) has signed a second US college conference and its first deployment in American football. The agreement is to provide its Whizzard sports solution to the Lone St...

The market may be falling today, but that hasn't stopped Biotron Ltd (ASX: BIT) shares from rocketing. In morning trade, the ASX healthcare stock is up almost 50% to 11 cents. Why is this ASX healthcare stock rocketing? Investors have been...

The ASX 200 slipped by -0.3% on Tuesday, tracking movements on Wall Street overnight.  The local market was dragged down by profit taking in the Tech and Comm Services sectors, while Energy was the only one to close in the green. Advancers...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  Local markets end +0.13% higher in quasi-comeback Consumer Staples soar on bumper Coles news, but offset by everyone else Small Caps led by Audeara on the back of a massive manufacturing sale   The indignation of Coles has led Consumer...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today. The telecommu...

We’ve all heard that “trend is your friend.” And who doesn’t like riding a trend? Trend or momentum trading involves buying a stock that has shown a significant movement in price or volume. Momentum traders believe that these trends will co...

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. There’s a bit of risk involved in momentum trading because in essence, you’re making a decision to buy a stock based on recent buying activiti...

The Week That Was The world looks very different this week after the addition of what Barclays economic team calls ‘a complex cocktail of geopolitical risk, mixed macro data, a nervous oil market,’ and a US Fed finding nice things to say ab...

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

Benchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm   Local markets have extended unexpected October losses on Wednesday as tech stocks, and the Financial Sector led losses on another bond-...

Benchmark index falls on Monday, closing out the day down 0.21% Utilities and Materials sectors edge higher, but Health Care anchors the benchmark into the red Small caps led by Galileo Mining, Infinity and last week’s rockstar Biotron...

Aussie Futures lower, but shares likely to show reilience RBA cash rate decision to be the main focus  Markets expect central bank to hold rates steady at 4.1 per cent on Tuesday   Futures for the benchmark ASX200 are trading 38 points l...

We look at which ASX stocks are trading on a momentum 52-week high and RSI are two indicators of momentum Simple Moving Average is also another measure of momentum   Last week, we looked at how traders find stocks that are trading with mo...

The Economic Week That Was As I return to the fold on a blistering Sunday arvo in Sydenham, my steel-toed boot into the midriff of American politics is out and the following tribute to breakmanship US style is in: At about 9pm on Saturday n...

This week’s Bulls N’ Bears profiled ASX runner is … Pioneer Resources. It jumped 95 per cent to join other impressive runners including MetalsTech, Biotron and Haranga Resources.

Benchmark index, up +0.34%, ends month on a positive after dropping -1.5% in September Materials Sector out front after strong run for iron ore, uranium prices Small caps led by, BIO, CXO and CZR   Local markets, led almost single-handedl...

Stockhead’s Top 10 at shortly-before-11-ish, produced in a tearing rush because it’s the Friday before a long weekend in the middle of the school holidays so of course everyone’s got ‘the flu’, or their grandma has died for the third time t...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Benchmark index settles almost -0.6% lower on Tuesday All sectors bar Healthcare and Financials in the red Small caps led by NickelSearch and Biotron A positive lead from Wall Street overnight didn’t sell well on local markets, which were...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Australian company Biotron (ASX:BIT) has announced that all participants in the Phase 2 COVID-19 clinical trial of its antiviral drug BIT225 have completed dosing, marking the end of the clinical phase of the study.

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Lumos surges on patent granted in Japan and Europe  Singular Health announces strategic investment in the US LGP’s founder steps down from CEO role   Lumos surges after patent granted in Europe and Japan Lumos Diagnostics (ASX:LDX) surged...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Sydney-based company Inventia Life Science has announced a new distribution agreement with Biotron Healthcare.

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Biotron (BIT) enters phase II of its COVID-19 clinical trial using its lead antiviral drug, BIT225, to test 60 male and female patients between 18-59 years old The trial will determine if BIT225 reduces the SARS-CoV-2 virus load in the b...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX 200 edges higher,  small cap index falls 0.44% 7 out of 11 sectors were in the green with Tech up 1.25% Downbeat RBA Governor speech highlights all the things that could go wrong with the economy   Last night the leads were decent, th...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Biotron (BIT) completes recruitment of the phase two HIV-1 clinical trial with its lead antiviral drug, BIT225The study will be carried out in people infected with HIV-1 who have achieved partial immune reconstitution despite treatmentParti...

Biotron (ASX:BIT) has announced the commencement of a human clinical trial of its lead antiviral drug BIT225 against COVID-19.

The ASX 200 falls 2.6%  after Wall St rout  Small caps recover manfully to be just 1% lower  AQC is turning out be a hell of a ride   Firstly, the Benchmark ASX 200 is down about 2.5% on Wednesday. It’s a fair whack, but hardly worse tha...